International journal of thyroidology

Korean Thyroid Association (대한갑상선학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Aggravation of Thyroid Goiter after Treatment with PD-1 Inhibitor for Breast Cancer in Patients with Underlying Hashimoto's Thyroiditis

기저 하시모토 갑상선염이 있던 유방암 환자에서 PD-1 억제제 투약 후 악화된 갑상선 종대의 증례

  • Kim, Hana (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Kim, Min Joo (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Song, Young Shin (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Cho, Sun Wook (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine)
  • Received : 2018.05.02
  • Accepted : 2018.08.09
  • Published : 2018.11.30
⟨ Previous Next ⟩

Abstract

Anti-programmed cell death-1 (PD-1) humanized monoclonal antibody inhibits PD-1 activity by binding to the PD-1 receptor on T-cells and blocking PD-1 ligands and induces immune tolerance of cancer cells. It has been widely used for various kinds of cancer treatment. However, many immune-related adverse events (irAEs) have been reported because it modulates our immune system. In this case study, we reported a case of 42-year-old woman with Hashimoto's thyroiditis who showed rapid aggravation of thyroid goiter and acute hyperventilation syndrome after treatment with PD-1 inhibitor as a neoadjuvant chemotherapy for breast cancer.

Keywords

References

  1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372(21):2018-28. https://doi.org/10.1056/NEJMoa1501824
  2. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PDL1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387(10027):1540-50. https://doi.org/10.1016/S0140-6736(15)01281-7
  3. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17(11):1497-508. https://doi.org/10.1016/S1470-2045(16)30498-3
  4. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35(19):2125-32. https://doi.org/10.1200/JCO.2016.72.1316
  5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54. https://doi.org/10.1056/NEJMoa1200690
  6. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372(26):2521-32. https://doi.org/10.1056/NEJMoa1503093
  7. de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 2016;101(11):4431-9. https://doi.org/10.1210/jc.2016-2300
  8. Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 2017;102(8):2770-80. https://doi.org/10.1210/jc.2017-00448
  9. Orlov S, Salari F, Kashat L, Walfish PG. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab 2015;100(5):1738-41. https://doi.org/10.1210/jc.2014-4560
  10. Hashimoto H. Zur Kenntnis der lymphomatosen Veranderung der Schilddruse (Struma lymphomatosa). Arch Klin Chir 1912;97:219-48
  11. Rapoport B. Pathophysiology of Hashimoto's thyroiditis and hypothyroidism. Annu Rev Med 1991;42:91-6. https://doi.org/10.1146/annurev.me.42.020191.000515
  12. Huber G, Staub JJ, Meier C, Mitrache C, Guglielmetti M, Huber P, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002;87(7):3221-6. https://doi.org/10.1210/jcem.87.7.8678
  13. Rieu M, Bekka S, Sambor B, Berrod JL, Fombeur JP. Prevalence of subclinical hyperthyroidism and relationship between thyroid hormonal status and thyroid ultrasonographic parameters in patients with non-toxic nodular goitre. Clin Endocrinol (Oxf) 1993;39(1):67-71. https://doi.org/10.1111/j.1365-2265.1993.tb01752.x
  14. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16(8):908-18. https://doi.org/10.1016/S1470-2045(15)00083-2
  15. Guaraldi F, La Selva R, Sama MT, D'Angelo V, Gori D, Fava P, et al. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Invest 2018;41(5):549-56. https://doi.org/10.1007/s40618-017-0772-1